Catalent's Open Letter to Customers Regarding Novo Holdings
Oct 21, 2024 · Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings. Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close. Alessandro Maselli to Remain President and CEO of Catalent Post-Close.
News and Events - Catalent
Feb 5, 2024 · Novo Holdings to Acquire Catalent. Feb 5, 2024. Catalent and Novo Holdings have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Oct 14, 2024 – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and ...
Novo Holdings to Acquire Catalent
Feb 5, 2024 · Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to this announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2 ...
Catalent Announces New Operating Structure
Jul 5, 2022 · Catalent's new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
Catalent to Acquire Metrics Contract Services for $475 Million
Aug 9, 2022 · Upon completion, the acquisition will strengthen Catalent’s capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs, while also expanding Catalent’s capacity to …
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Jan 5, 2023 · Catalent & Sarepta partner to manufacture delandistrogene moxeparvovec, an advanced candidate to treat Duchenne muscular dystrophy.
News Details - Catalent
Aug 29, 2023 · SOMERSET, N.J.-- (BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better biopharmaceutical treatments for patients worldwide, today announced several initiatives reflecting its ongoing commitment to strong corporate governance and shareholder value creation.
Moderna and Catalent Partner on COVID-19 Vaccine Candidate
Jun 25, 2020 · Moderna and Catalent today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.
Catalent Stockholders Approve Transaction with Novo Holdings
May 29, 2024 · Based on the preliminary count of the voting results from today’s Special Meeting, Catalent stockholders voted to approve the transaction with 99.2% of ballots cast in favor of the proposed transaction.